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Arandomized,double-blind,placebo-controlled study wasconducted to evaluatetheeﬃcacyofGutGard,anextract ofGlycyrrhiza
glabra,inpatientswithfunctionaldyspepsia. Theprimaryoutcomevariablesofthestudy werethechangeintheseveritysymptoms
and the global assessment of eﬃcacy. The quality of life was evaluated as a secondary outcome measure. The patients received
either placebo or GutGard (75mg twice daily) for 30 days. Eﬃcacy was evaluated in terms of change in the severity of symptoms
(as measured by 7-point Likert scale), the global assessment of eﬃcacy, and the assessment of quality of life using the short-
form Nepean Dyspepsia Index. In comparison with placebo, GutGard showed a signiﬁcant decrease (P ≤ .05) in total symptom
scores on day 15 and day 30, respectively. Similarly, GutGard showed marked improvement in the global assessment of eﬃcacy in
comparison to the placebo. The GutGard group also showed a signiﬁcant decrease (P ≤ .05) in the Nepean dyspepsia index on
day 15 and 30, respectively, when compared to placebo. GutGard was generally found to be safe and well-tolerated by all patients.
GutGard has shown signiﬁcant eﬃcacy in the management of functional dyspepsia.
1.Introduction
Among various gastrointestinal disorders, functional dys-
pepsia is one of the most common and costliest clinical con-
ditionsingeneralmedicalpractices.Dyspepsiaintheabsence
of clinically identiﬁable, structural gastrointestinal lesions is
known as functional dyspepsia or nonulcer dyspepsia [1, 2].
Thegeneralsymptoms offunctional dyspepsia includeupper
abdominal fullness, epigastric pain, belching, bloating, early
satiety, nausea, vomiting, regurgitation, heartburn, and loss
of appetite [1–5].
Thoughtheprognosisremainspoorlydeﬁned,functional
dyspepsia is prevalent worldwide. In Europe and North
America, 20% of patients with dyspeptic symptoms had
consulted either physicians or hospital specialists; more than
50% patients were on medication often and around 30% of
dyspeptics reported taking days oﬀ work or schooling [5–7].
Chang reviewed the epidemiology of functional dyspepsia
and reported the annual incidence of dyspepsia around
9-10%[8].Long-termstudiesindicatethatmorethan80%of
patient populations aﬀected by chronic functional dyspepsia
were likely to be persistent after 6-7 years of follow-up [9–
11].
Although functional dyspepsia does not seem to be life
threatening, the impact remains stressful and leads to huge
medical expenses. The dyspeptic patients reported signif-
icantly reduced quality of life when compared to general
healthy public [8]. As per the published reports, the direct
and indirect economic burden due to functional dyspepsia
was found to be huge and also has considerable impact on2 Evidence-Based Complementary and Alternative Medicine
productivity [12]. To achieve a sense of overall well-being, to
reduce the cost of treatment and to maintain the quality of
life, eﬀective and safe remedies would be a welcome addition
for patients with functional dyspepsia.
Despite the availability of several treatments, the phar-
macological interventions were found to be inconclusive
and experienced with varied eﬃcacy. With the increasing
popularity of medicinal plants globally, many herbal ex-
tracts/preparations are evaluated for management of gas-
trointestinal disorders. The roots and rhizomes of licorice
(Glycyrrhiza glabra Linn; family: Leguminosae) have been in
traditional use for several centuries. The roots of G. glabra
have expectorant, diuretic, laxative, sedative, antipyretic, an-
timicrobial, hepatoprotective, antioxidant, and antiadhesive
properties [13–16]. In addition, licorice has been reported
for enhancing gastric mucus secretion and antiulcer activity
[17, 18].
In vitro study on glabridin and glabrene (ﬂavonoids
present in licorice root) revealed anti-Helicobacter pylori (H.
pylori) activity, and the licoriceextract has also shown signif-
icant beneﬁcial eﬀect on all forms of H. pylori infection [19,
20]. In an earlier in vivo study, deglycyrrhizinated licorice
(DGL) was found to be eﬀective in alleviation of ulcer in
aspirin-induced gastric mucosal damage in rats [21]. The
curativeeﬀectofDGLingastric ulcerpatientswasconﬁrmed
during 1970s by clinical trials [22, 23]. Clinically DGL has
been used as a main source for the treatment of ulcerative
conditions of gastrointestinal disorders like peptic ulcer,
cankersores, inﬂammatory bowel diseases, and so forth [24].
The antiulcerproperty of licoriceextract was also established
in gastric ulcer patients.
Acute oral toxicity study of GutGard, an extract of G.
glabra, was found to be safe up to 5000mg/kg in rats. Re-
cently, Chandrasekaran et al. conﬁrmed the dual inhibitory
eﬀect of GutGard on derivatives of COX and LOX inﬂam-
matory pathways [25]. Specialized licorice extracts have
been recently shown to exhibit excellent antiulcer activity in
experimental animal models. GutGard has shown marked
improvement at diﬀerent doses (12.5, 25, and 50mg/kg)
in pylorus ligation, cold-restraint stress, and indomethacin
induced gastric mucosal injury in albino Wistar rats and the
eﬀects were found to be dose dependent [26].
From the above considerations, G. glabra is found to be
an eﬀective agent in the management of several gastroen-
terological disorders. This study was particularly aimed to
assesstheeﬃcacyandtolerabilityofGutGardinpatientswith
functional dyspepsia.
2.Materialsand Methods
2.1. Study Design. The test substance GutGard is a ﬂavonoid
rich, root extract of Glycyrrhiza glabra developed by Natural
Remedies, Bangalore, India. GutGard has following phy-
tochemical speciﬁcations, namely, glabridin (≥3.5%w/w),
glabrol (≥0.5%w/w), eicosanyl caﬀeate (≥0.1%w/w), doco-
syl caﬀeate (≥0.1%w/w), glycyrrhizin (≤0.5%w/w), and
total ﬂavonoids (≥10%w/w). The clinical investigation was
conducted over a period of four months (December 2009 to
March 2010)asadouble-blind,placebo-controlled,random-
ized manner in two trial centers in Bangalore, India, which
includedascreening procedure,selectionofparticipants, test
medication, and ﬁnally posttreatment evaluation. Fifty-four
patients were initially diagnosed for functional dyspepsia
according to Rome-III criteria [27] and enrolled for the
study. Screening was done by physical examination (weight,
height, heart rate, systolic and diastolic blood pressure
(BP), etc.) and biochemical evaluation before the patients
were assigned into the trial. The patients were recruited
according to the inclusion and exclusion criteria (Table 1).
The purpose and methodology of the clinical trial were
explained in simple, understandable language to all the
patients. Before randomization, the subjects were asked to
completely understand and sign the informed consent form.
A copy of informed consent form was issued to trial par-
ticipants. In addition, investigators clariﬁed queries/doubts
of trial subjects if any, prior to signing the consent form.
Consent was taken by the investigators of the clinical trial.
All the subjects were informed that they can withdraw at any
time from participating in the trial without any prior notice.
This study was conducted after approval by the Institutional
Ethics Committee.
2.2. Randomization and Blinding. After the diagnoses, base-
line status was established, four were excluded, and 50
patients were randomly assigned to placebo (n = 25) and
GutGard (n = 25) groups (Figure 1). A list of unique integer
random numbers considered as patient code (i.e., random
allocation sequence) was generated using a computer-aided
programme. As per the random allocation sequence, the
containers(eitherplaceboorGutGardcapsules) were labeled
with unique random numbers. The randomization sequence
was developed at Natural Remedies Pvt. Ltd., Bangalore,
India, and forwarded to study centre. The entire process was
performed in a conﬁdential manner and all the concerned
in study centre namely, investigators, patients, and other
supportive staﬀ were unaware of the random allocation
sequence. The participants fulﬁlling the selection criteria of
the study and after obtaining the written informed consent
were enrolled by thestudy investigatorsand subsequentlythe
pharmacist dispensed the study medication to the partici-
pants taking into consideration the order of enrollment and
as per the random allocation sequence. The investigators,
patients, and pharmacist dispensing the interventions were
all concealed to group assignment. The blinding process was
maintained till all the data were compiled and veriﬁed for
accuracy and then forwarded for statistical analysis.
Test medication was dispensed by the pharmacist in a
container with 30 capsules on day 0 and day 15. The patients
were instructed to take placebo or GutGard (75mg twice
daily) with a glass of water after food (one capsule morning
and one in the night). The investigational substance was
stored as per the recommendation in accessible, controlled
area, and pharmacists were accountable for the same.
Patients were informed to visit the trial centers on day 15
and day 30 for follow-up. At each visit, the investigators
informed the patients to bring the capsule container, and
remaining capsule (unused) counts were performed. PatientEvidence-Based Complementary and Alternative Medicine 3
Table 1: Inclusion and exclusion criteria.
Inclusion criteria
(i) Diagnosis of functional dyspepsia/nonulcer dyspepsia by fulﬁlling Rome-III criteria
(ii) Should be suﬀering with at least 4 or more symptoms mentioned below and with total symptom score of 20 or more based on
7-point Likert scale
(a) Upper abdominal fullness
(b) Upper abdominal pain
(c) Belching
(d) Bloating
(e) Early satiety
(f) Nausea
(g) Vomiting
(h) Regurgitation
(i) Heartburn
(j) Loss of appetite
Exclusion criteria
(i) Age less than 18 years or over 65 years
(ii) Advanced chronic illness that would impair follow-up or monitoring
(iii) Pregnancy or breast feeding
(iv) Previous surgery for ulcers
(v) Subjects with previous history of gastroesophageal reﬂux
(vi) Subjects with concomitant symptoms of the irritable bowel syndrome
(vii) Drug and alcohol abuse
(viii) Mental illness or dementia
Analysed (n = 25)
♦Excluded from analysis (give reasons) (n = 0)
Analysed (n = 25)
♦Excluded from analysis (give reasons) (n = 0)
Allocated to intervention (n = 25)
♦Received allocated intervention (n = 25)
♦Did not receive allocated intervention
(give reasons) (n = 0)
Allocated to intervention (n = 25)
♦Received allocated intervention (n = 25)
♦Did not receive allocated intervention
(give reasons) (n = 0)
Allocation
Analysis
Assessed for eligibility (n = 54)
Randomized (n = 50)
Enrollment
Placebo GutGard
Follow up
Lost to followup (give reasons) (n = 0)
Discontinued intervention (give reasons) (n = 0)
Lost to followup (give reasons) (n = 0)
Discontinued intervention (give reasons) (n = 0)
Excluded (n = 4)
♦Not meeting inclusion criteria (n = 3)
♦Declined to participate (n = 1)
♦Other reasons (n = 0)
Figure 1: Flow chart of disposition of patients.4 Evidence-Based Complementary and Alternative Medicine
who took completely the issued capsules was considered to
be compliant to the study medication.
2.3. Assessment of Eﬃcacy and Tolerability. The primary
outcomevariablesofthestudywerethechangeintheseverity
symptoms and the global assessment of eﬃcacy. A list of
10 gastrointestinal symptoms, namely, upper abdominal
fullness, upper abdominal pain, belching, bloating, early
satiety, nausea, vomiting, regurgitation, heartburn, and loss
of appetite, were considered. The patients were asked to
rate themselves for the severity of gastrointestinal symptoms
using 7-point Likert scale [28], and the change in severity of
symptoms was assessed on days 0, 15, and 30. On day 30, the
overall changes in dyspeptic symptoms were calculated, and
the measurement was categorized into ﬁve grades (symp-
tom free, markedly improved, moderately improved, not
changed, and deteriorated) for global assessment of eﬃcacy-
an index for the overall response to 30 days of intervention.
The quality of life was evaluated using the short-form
Nepean Dyspepsia Index (NDI) as a secondary outcome
measure. The NDI is a disease-speciﬁc health-related qual-
ity of life (HRQOL) instrument consisting of a 10-item
questionnaire examining the inﬂuence of dyspepsia on
ﬁve elements (subscales) in patient’s health, like tension,
interferencewithdailyactivities,disruptiontoregulareating/
drinking, knowledge/control over disease symptoms, and
interference with work/study. Based on the subscales, the
scores of NDI were assessed on days 0, 15, and 30. This total
score of NDI gives information on quality of life and impact
of illness of dyspeptic patients [29, 30]. The primary and
secondary assessment of eﬃcacy was achieved by face to face
discussions with trial patients.
Clinical laboratory investigations were done before and
after the interventions in order to assure the safety. The
study imposed that medications potentially aﬀecting the
gastrointestinal tract were restricted during the trial period.
2.4. Data Analysis. The required sample size for diﬀerence
between two means, that is, for a two-sample t-test, was
estimated using Snedecor and Cochran formula n = 1+
2C (s/d)
2 a c c o r d i n gt oD e l le ta l .[ 31]a se s t i m a t e df r o m
Holtmann et. al. [1]w i t hα value of 0.05 and 1 − β =
0.9 0 .B a s e do nt h i s ,t h er e q u i r e ds a m p l es i z ec a l c u l a t e d
f o re a c ha r mo fG u t G a r do rp l a c e b ow a s2 4s u b j e c t so ra
total of 48 for the complete study. Twenty-ﬁve participants
from each intervention were considered for the statistical
analysis. Characteristics of patients at baseline of two groups
were compared by independent samples t-test. The change
in total symptom scores and Nepean dyspepsia index of
each patient on day 15 and day 30 were calculated by
subtracting the total symptom scores and Nepean dyspepsia
index of day 0 (baseline) from respective observation of
each parameters recorded on day 15 and day 30. The total
symptoms scores and Nepean dyspepsia index (change from
the baseline) of two groups were analyzed by independent
samples t-test. Eﬀect size, which estimates the change in
individual symptom scores relative to the variability in the
individual symptoms scores at baseline, was calculated using
the following formula.
Eﬀect size
=
Individual symptoms scores

day 15 or 30 −day 0

Standard deviation at baseline
.
(1)
As c a l ew i t ha ne ﬀect size of 0.8 or larger was considered
as magnitude of improvement. The global assessment of
eﬃcacy observed in two groups was analyzed by proportion
Z test [32]. Laboratory investigations recorded on day 0 and
day 30 were also analyzed by independent samples t-test.
The abovestatistical applicationswere performed using SPSS
software. A two-tailed (alpha = 2) probability value P ≤ .05
was considered to be statistically signiﬁcant.
3.Results
Out of ﬁfty-four patients screened for eligibility, three
patients were excludedfor not meeting inclusioncriteria and
one patient declined to participate. A total of 50 patients
were randomly assigned into two groups, namely, placebo
(n = 25; 16 males and 9 females) and GutGard (n = 25;
15 males and 10 females), and subsequently considered for
analysis (Figure 1).
3.1.DemographicCharacteristics ofPatients. Meancharacter-
istics of treated group versus placebo group at baseline were
f o u n dt ob ec o m p a r a b l ee x c e p tf o ra g ea n dd i a s t o l i cB Pi n
GutGard treated group which were still within normal range
(Table 2).
3.2. Primary and Secondary Outcome Measures. The change
in total symptom scores from baseline of diﬀerent groups
was summarized in Table 3.I nc o m p a r i s o nw i t hp l a c e b o
group, GutGard treated group showed a signiﬁcant decrease
(P ≤ .05) in total symptom scores on day 15 and day 30,
respectively. The eﬀect size of individual symptom scores of
diﬀerent groups was summarized in Table 5. The magnitude
of improvement in terms of eﬀect size after 15 and 30 days
of treatment was apparently more in GutGard treated group
except in “early satiety” as compared with placebo.
With respect to global assessment of eﬃcacy, one patient
from GutGard group was completely free from dyspeptic
symptoms while none of the patients in placebo group
reported symptoms free. Out of 25 patients in each inter-
vention, none in placebo and 14 in GutGard showed marked
improvement in symptoms, and the proportion of patients
was signiﬁcantly higher (P ≤ .05) in GutGard intervention
than that in placebo. Moderate improvement was noticed in
nine patients in GutGard treated group and eleven patients
in placebo group. The symptoms remained unchanged in
fourteen patients of the placebo group while only one
in GutGard group and the diﬀerence in proportion was
signiﬁcantly less (P ≤ .05) in GutGard treated group than
the placebo. None of the patients in both groups complained
deteriorated condition (Table 4). GutGard supplementationEvidence-Based Complementary and Alternative Medicine 5
Table 2: Characteristics of the patients at baseline (mean ± SE).
Parameters Placebo (n = 25) GutGard (n = 25)
Patients (Male/Female) 16/09 15/10
Age (years) 45.16 ± 2.06 38.12 ± 1.84∗
Weight (kg) 67.55 ± 1.75 66.38 ± 2.15
Height (cm) 163.93 ± 1.69 164.29 ± 1.06
Heart rate/min 83.04 ± 1.48 80.32 ± 1.36
BP systolic (mmHg) 128.00 ± 2.10 122.64 ± 1.92
BP diastolic (mmHg) 84.24 ± 0.80 79.92 ± 0.88∗
Total symptoms scores of dyspepsia 28.68 ± 0.62 29.96 ± 0.55
Nepean Dyspepsia Index 34.40 ± 1.02 35.64 ± 0.65
∗P ≤ .05 versus placebo.
Table 3: Eﬃcacy of GutGard on improvement of total symptom scores and Nepean dyspepsia index (mean ± SE).
Groups Total symptom scores (Change from baseline) Nepean dyspepsia index (Change from baseline)
Day 15 Day 30 Day 15 Day 30
Placebo (n = 25) −5.08 ± 0.57 −8.24 ± 0.76 −4.04 ± 0.49 −6.56 ±0.85
GutGard (n = 25) −11.32 ± 0.77∗ −15.20 ± 0.71∗ −12.08 ± 0.82∗ −19.56 ± 0.85∗
∗P ≤ .05 versus placebo.
resulted in a signiﬁcant decrease (P ≤ .05) in Nepean
dyspepsia index on day 15 and day 30, respectively, versus
placebo group (Table 3).
3.3. Laboratory Investigations. The blood parameters carried
outonday0and day30inGutGardand placebogroupswere
within normal limits. Though, there were marginal increase
in random blood sugar on days 0 and 30 and decrease
in serum creatinine on day 0 in GutGard treated group,
these changes were all within the speciﬁed normal range
(Table 6). There was no study medication-related adverse
eﬀect reported during the complete intervention period.
4.Discussion
Saad and Chey, in a review on current and emerging ther-
apies for functional dyspepsia, enlisted various approaches
employed such as dietary manipulations, modern medicines
directed at single or multiple targets within the gastrointesti-
nal and central nervous systems, psychological interventions
and of late, and complementary and alternative traditional
medicinal systems [11]. Treatment with synthetic medicines,
though found to be eﬀective and common, is accompanied
with several side eﬀects. In addition, these modern drugs are
expensive, alter the normal gastrointestinal functions, and at
times may aggravate the existing conditions [24].
Use of herbal supplements in the management of gas-
trointestinal complications, especially for functional dys-
pepsia, has attracted researchers worldwide. Several herbal
formulations have been reported with clinically proven
eﬃcacy and safety in the recent past, and screening ofmedic-
inal plants for potent antidyspeptic agents appears to be
continuing [33]. From the published literature, G. glabra,
a perennial, temperate zone herb [24], is reported to possess
a variety of pharmacological properties such as demulcent
[22, 34], anti-inﬂammatory [18], and antiulcer activities
[35] that can be attributed to the beneﬁcial eﬀects of
GutGard on gastrointestinal system. A preclinical study on
GutGardinalbinoWistarratsrevealedstatisticallysigniﬁcant
improvements in endpoints, namely, ulcer index, volume,
and total acidity of gastric contents in various models of
antiulcer activity. Also the study reported potent antioxidant
activity with high hydrophilic and lipophilic oxygen radical
absorbance capacity (ORAC) value and thereby validated its
cytoprotective eﬀect [26].
In the current study, eﬀectiveness of GutGard (75mg)
twice daily for 30 days was evaluated in patients with func-
tional dyspepsia using changes in the pre- and postinterven-
tion scores of the study outcome measures. On comparison,
GutGard exhibited signiﬁcant reduction in total symptom
scores on day 15 and day 30, marked improvement in
global assessment of eﬃcacy, and signiﬁcantly decreased the
Nepean dyspepsia index on day 15 and day 30 than the
placebo group. Analysis of eﬀect on individual symptoms
of functional dyspepsia has also revealed excellent improve-
ments in GutGard treated group except for early satiety as
compared with the placebo group.
Despite well established, favorable eﬀects of G. glabra on
digestive system, the available literature indicates the lack of
adequate clinical studies on eﬀect of licorice/licorice prepa-
rations, as single entity, in functional dyspeptic patients, and
connotes the importance of the present study as one of the
earliest double-blind, placebo-controlled, clinical trials on
eﬃcacy of licorice in the control of functional dyspepsia.
In the present study, changes in total symptoms scores
from baseline values were evaluated, and GutGard sup-
plementation has shown to considerably improve the total
symptoms scores. Coon and Ernst, in a review on eﬀects
of selected herbal medicinal products in patients with func-
tional dyspepsia, observed that though various techniques6 Evidence-Based Complementary and Alternative Medicine
Table 4: Eﬀect of GutGard on improvement of global assessment of eﬃcacy.
Groups
Global assessmentof eﬃcacy
Symptom
free Z-value Markedly
improved Z-value Moderately
improved Z-value Not
changed Z-value Deteriorated Z-value
Placebo
(n = 25) 0 (0) — 0 (0) — 11 (44) — 14 (56) — 0 (0) —
GutGard
(n = 25) 1 (4) 0.00 14 (56) 4.10∗ 9 (36) 0.29 1 (4) 3.70∗ 0( 0 ) —
Values in parentheses represent the percentage of patients in each category.
∗P ≤ .05 versus placebo.
Table 5: Eﬀect of GutGard on the individual symptoms scores.
Parameter Groups (n = 25) Day 15 Day 30
Change in score Eﬀect size Change in score Eﬀect size
Upper abdominal fullness Placebo −0.52 0.393 −0.88 0.665
GutGard −1.72 5.186 −2.28 6.875
Upper abdominal pain Placebo −0.04 0.084 −0.16 0.336
GutGard −1.24 1.127 −1.88 1.709
Belching Placebo −0.76 0.734 −0.96 0.927
GutGard −1.16 2.352 −1.40 2.838
Bloating Placebo −0.8 0.755 −1.08 1.019
GutGard −1.04 1.733 −1.36 2.267
Early satiety Placebo −0.88 0.848 −1.04 1.002
GutGard −0.52 0.770 −0.72 1.065
Nausea Placebo −0.16 0.225 −0.28 0.393
GutGard −0.56 1.065 −0.92 1.749
Vomiting Placebo −0.16 0.210 −0.32 0.419
GutGard −0.68 1.133 −0.80 1.333
Regurgitation Placebo −0.28 0.211 −0.80 0.603
GutGard −1.52 1.675 −1.84 2.028
Heartburn Placebo −0.84 0.899 −1.44 1.541
GutGard −1.52 1.568 −2.12 2.187
Loss of appetite Placebo −0.64 0.492 −1.28 0.985
GutGard −1.36 0.905 −1.88 1.252
were used for measurement of total symptoms scores, few
of them were seem to be nonvalidated [33]. Given this
consideration, the current study employed the validated 7-
point Likert scale reported by van Zanten in Alimentary
Pharmacology and Therapeutics [28]. Dietary preparations
containing licorice as one of the key ingredients have also
shown considerable eﬃcacy in patients with functional
dyspepsia. A meta-analysis of double-blind, randomized,
clinical trials on a polyherbal combination containing
licorice (Iberogast) demonstrated excellent overall thera-
peutic eﬀect in the treatment of functional dyspepsia. The
dose and duration of the herbal actives were kept the
same in all the individual studies. The ﬁndings showed
a substantial improvement of symptoms with Iberogast
but varying superiority to placebo pertinent to dyspepsia-
speciﬁc gastrointestinal symptom score [36]. A systematic
review on eﬃcacy and tolerability of Iberogast by Melzer
et al. also validated the therapeutically related decrease of
gastrointestinal symptom-scores in patients with functional
dyspepsia [37].
Patients’ assessments of global eﬃcacy as measured by
the proportion of patients without symptoms or with
marked improvements have shown the superiority of Gut-
Gard treatment (56%) over placebo (0%) and have been
found to be in accordance with the changes in the severity
of total symptoms. Likewise, the disease-speciﬁc quality of
life improvements evaluated by NDI also revealed signiﬁcant
advantages resulted by GutGard administration. Although
the improvements in quality of life is viewed as a secondary
outcome measure in ongoing clinical trials, Talley et al.
expressed the prospective use of improvements in the
Nepean Dyspepsia Index as a primary objective of treatment
infutureclinicalinvestigationsongastrointestinal conditions
such as functional dyspepsia [29].
With respect to eﬀects on individual symptoms, as
evident from eﬀect size, GutGard notably decreased theEvidence-Based Complementary and Alternative Medicine 7
Table 6: Results of laboratory blood parameters (mean ± SE).
Parameters Day 0 Day 30
Placebo (n = 25) GutGard (n = 25) Placebo (n = 25) GutGard (n = 25)
Haemoglobin(g/dL) 13.30 ± 0.31 13.40 ± 0.33 13.37 ± 0.30 13.58 ± 0.28
Random blood sugar(mg/dL) 86.64 ± 2.76 103.6 ± 2.08∗ 91.44 ± 1.59 100.72 ± 2.30∗
Serum creatinine(mg/dL) 0.93 ± 0.02 0.83 ± 0.03∗ 0.88 ± 0.02 0.88 ± 0.02
Serum glutamic oxaloacetic transaminase(IU/L) 20.64 ± 1.56 20.50 ± 1.45 20.20 ± 1.08 17.28 ± 1.24
Serum glutamic pyruvic transaminase(U/L) 23.48 ± 1.73 28.03 ± 1.71 20.80 ± 1.07 23.20 ± 1.19
∗P ≤ .05 versus placebo.
intensity of symptoms such as upper abdominal fullness and
epigastric pain which are considered as important symp-
toms of functional dyspepsia [38, 39]. Correspondingly, the
other parameters of GutGard group also exhibited marked
improvements on day 15 and day 30 of the study period
except for “early satiety” symptom wherein the eﬀects of
the investigational medication and the placebo were found
to be comparable. Hence, the overall improvements in total
symptoms scores can be attributed to the cumulative and
uniform eﬀects of licorice extract on almost all individual
symptoms of functional dyspepsia.
On the other hand, relevant gastrointestinal eﬀects(anti-
ulcer activity) of G. glabra may provide noteworthy insights
in understanding the pharmacological beneﬁts in alleviation
of functional dyspepsia. A double-blind clinical study on
DGL exhibited ulcer healing properties upon administration
of capsules (each with 400mg actives) for 8 weeks and
subjective improvements were recorded in 90% subjects
[2]. Lakworthy and Holgate reported antiulcer activity after
administrationoftabletscontaining380mgDGLinallthe32
patients (100%) endoscopically diagnosed having duodenal
ulcer and with chronic history. The beneﬁcial eﬀects were
found to be improved as the duration of intervention
extended since 56% of the patients recovered after 12 weeks
of treatment whereas 78% recuperated after 16 weeks [23].
These ﬁndings were in accordance with the current study
wherein total symptom scores and NDI were found to be
improved over a period of 15 and 30 days.
As commonly reported in several clinical trials, the
presentinvestigationalsoobservedimprovementsintotalsy-
mptoms scores of placebo group. However, the improve-
ments were found to be insigniﬁcant and not in concurrence
with the outcomes of other parameters. In addition to
true placeboeﬀect,contributionof spontaneousﬂuctuations
resulting in improvements of symptoms in functional dys-
peptic patients is reported in the published clinical studies
[3]. Placebo controls are ethically justiﬁable if usage does not
expose research participants to excessive risks of harm [40].
Scientiﬁcally,placebocontrolledtrialsrequiresmallersample
size, generate reliable scientiﬁc evidencefor the evaluation of
new substances, and have better internal validity though are
less relevant to patient management and have low external
validity [41].
No treatment-related adverse eﬀects were reported dur-
ing the study, and GutGard administration was found to
be safe and well tolerated by all patients during the com-
plete intervention period. Despite few side eﬀects generally
reported with the use of G. glabra, patients of the present
study did not experience any such side eﬀe c tt h a ti n d i c a t e s
the widely safe nature of the dietary supplement [42]. The
available published literature on clinical studies of licorice
extracts/formulations also did not report any signiﬁcant
adverse events at various dosage regimens [22, 23]. Isbrucker
and Burdock, based on the existing scientiﬁc evidence and
considering the importance of licorice as a popular food
ingredient, reviewed the safety of the medicinal herb and
asserted that the current intake levels of licorice products
seems to be safe [43].
5.Conclusion
The ﬁndings of the randomized double-blind, placebo-
controlled, clinical trial on GutGard, the root extract of G.
glabra, revealed signiﬁcant decrease in symptoms scores in
concordance with improvements in almost all individual
symptoms and found to be superior to placebo group
in the management of functional dyspepsia. The present
study also exhibited signiﬁcantly improved quality of life as
evidenced by improved NDI upon administration of the test
substance at 75mg twice daily for 30 days. Hence, GutGard
supplementation can be considered as a safe and eﬀective
remedy for patients with functional dyspepsia.
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